GSK’s Shingrix Vaccine Can Reach Millions More
US FDA Clears New Claim In Immunocompromised Adults
The shingles vaccine could potentially be used in about three million immunocompromised people, according to GSK, but CDC’s advisory committee will weigh in with recommendations.
You may also be interested in...
While demand for Shingrix is expected to return in the US, the slow process of COVID-19 vaccination in many other countries will delay its uptake.
The second quarter could mark a financial turning point for big pharma as demand rebounds from the pandemic, but variability remains across portfolios and therapeutic areas.
Phase III trials found vaccine effectiveness was 68.2% in recipients with autologous hematopoietic stem cell transplant and 87.2% in those with hematologic malignancies, GSK tells Advisory Committee on Immunization Practices.